title: Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir.
authors.forename: Mauro
authors.initials: M
authors.lastname: Zaccarelli
authors.forename: Daniela
authors.initials: D
authors.lastname: Zinzi
authors.forename: Maria Paola
authors.initials: MP
authors.lastname: Trotta
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Liuzzi
authors.forename: Pietro
authors.initials: P
authors.lastname: Sette
authors.forename: Patrizia
authors.initials: P
authors.lastname: Marconi
authors.forename: Rosa
authors.initials: R
authors.lastname: Acinapura
authors.forename: Andrea
authors.initials: A
authors.lastname: Antinori
mesh_terms: D000069446:Atazanavir Sulfate; D006679:HIV Seropositivity / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000453:epidemiology*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D013557:Switzerland / Q000453:epidemiology; D017211:Treatment Failure; D016312:Treatment Refusal
chemical_list: D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate